Nutraceuticals for prostate cancer chemoprevention: From molecular mechanisms to clinical application

Expert Opinion on Investigational Drugs

Volumn 22, Issue 12, 2013, Pages 1613-1626

  Wang, Zhijun ^a   Fan, Jeffery ^a   Liu, Mandy ^a   Yeung, Steven ^a   Chang, Andy ^a   Chow, Moses Ss ^a   Pon, Doreen ^a   Huang, Ying ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Chemoprevention; Genistein; Green tea polyphenol; Lycopene; Nutraceuticals; Omega 3 fatty acids; Prostate cancer; Quercetin; Resveratrol; Sulforaphane; Vitamin D

Indexed keywords

CALCITRIOL; CATECHIN; COLECALCIFEROL; CURCUMIN; DOCOSAHEXAENOIC ACID; DUTASTERIDE; FINASTERIDE; FISH OIL; GENISTEIN; GREEN TEA EXTRACT; HISTONE DEACETYLASE INHIBITOR; ICOSAPENTAENOIC ACID; ISOFLAVONE; ISOFLAVONE DERIVATIVE; ISOTHIOCYANIC ACID DERIVATIVE; LINOLENIC ACID; LYCOPENE; MESSENGER RNA; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PACLITAXEL; POLYPHENOL; POLYPHENON E; PROSTATE SPECIFIC ANTIGEN; QUERCETIN; RESVERATROL; SULFORAPHANE; VITAMIN D;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER PREVENTION; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE PROGRESSION; CELL INVASION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CYTOTOXICITY; DIET SUPPLEMENTATION; DNA DAMAGE; DNA METHYLATION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TRANSFORMATION; ENVIRONMENTAL FACTOR; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; IN VITRO STUDY; LIFESTYLE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ONCOGENE RAS; OXIDATIVE STRESS; PROMOTER REGION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RNA STABILITY; TEA; THERAPY EFFECT; TUMOR INVASION; ULTRAVIOLET B RADIATION;

ANIMALS; ANTICARCINOGENIC AGENTS; DIETARY SUPPLEMENTS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84887642308     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.833183     Document Type: Review

References (114)

1. Thompson I, Tangen C, Tolcher A, et al. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst 2001;93: 219-25
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
4. Sorensen KD, Orntoft TF. Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev Mol Diagn 2010;10: 49-64
5. Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int 2011;108:806-13
6. Bemis DL, Katz AE, Buttyan R. Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs 2006;15:1191-200
7. Van Poppel H, Tombal B. Chemoprevention of prostate cancer with nutrients and supplements. Cancer Manag Res 2011;3:91-100
8. Parnes HL, House MG, Tangrea JA. Prostate cancer prevention: strategies for agent development. Curr Opin Oncol 2013;25:242-51.. Recent review on prostate cancer prevention trials of 5a-reductase inhibitors.
9. Canby-Hagino ED, Thompson IM. Mechanisms of disease: Prostate cancer-a model for cancer chemoprevention in clinical practice. Nat Clin Pract Oncol 2005;2:255-61.. Nice review on mechanisms of prostate cancer and chemoprevention.
10. Violette PD, Saad F. Chemoprevention of prostate cancer: myths and realities. J Am Board Fam Med 2012;25:111-19
11. Lippert MC, McClain R, Boyd JC, et al. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 1999;86:2642-8
12. Nam RK, Fleshner N, Rakovitch E, et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: An epidemiological analysis. J Urol 1999;161:1521-4
13. Kalra EK. Nutraceutical-definition and introduction. AAPS PharmSci 2003;5:E25.. Introduction of the definition of nutraceuticals.
14. Rittmaster RS. Chemoprevention of prostate cancer. Acta Oncol (Madr) 2011;50(Suppl 1):127-36
15. Madu CO, Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer 2010;1:150-77
16. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81
17. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69
18. Sciarra A, Di Silverio F, Salciccia S, et al. Inflammation and chronic prostatic diseases: Evidence for a link Eur Urol 2007;52:964-72
19. Boyd LK, Mao X, Lu YJ. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol 2012;9:652-64
20. Cimino S, Sortino G, Favilla V, et al. Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev 2012;2012:632959. Nice review of polyphenols as prostate cancer chemopreventive agents.
21. Ho E, Beaver LM, Williams DE, et al. Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr 2011;2:497-510
22. Nelson WG. Prostate cancer prevention. Curr Opin Urol 2007;17:157-67
23. Andriole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: The scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004;172:1399-403
24. Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 2008;179:1235-42
25. Liao S, Hiipakka RA. Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun 1995;214:833-8
26. Halliwell B. Free radicals and antioxidants: updating a personal view. Nutr Rev 2012;70:257-65
27. Cui X. Reactive oxygen species: The Achilles heel of cancer cells Antioxid Redox Signal 2012;16:1212-14
28. Sporn MB, Liby KT. Cancer chemoprevention: scientific promise, clinical uncertainty. Nat Clin Pract Oncol 2005;2:518-25
29. Gupta SC, Hevia D, Patchva S, et al. Upsides and downsides of reactive oxygen species for cancer: The roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 2012;16:1295-322
30. Kwak MK, Kensler TW. Targeting nrf2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 2009;244:66-76
31. Ho E, Beaver LM, Williams DE, et al. Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr 2011;2:497-510
32. Ho E, Clarke JD, Dashwood RH. Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr 2009;139:2393-6
33. Chiyomaru T, Yamamura S, Zaman MS, et al. Genistein suppresses prostate cancer growth through inhibition of oncogenic microrna-151. PLoS One 2012;7(8):e43812
34. Luo J-H, Ding Y, Chen R, et al. Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancer. Am J Pathol 2013;182(6):2028-36
35. Parasramka MA, Ho E, Williams DE, et al. Micrornas, diet, and cancer: new mechanistic insights on the epigenetic actions of phytochemicals. Mol Carcinog 2012;51:213-30
36. Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics 2008;3:300-9
37. Gravina GL, Ranieri G, Muzi P, et al. Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells. Oncol Rep 2013;29:1189-95
38. Yu SW, Khor TO, Cheung KL, et al. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of tramp mice. PLoS One 2010;5(1):e8579
39. Yi B, Piazza GA, Su X, et al. Microrna and cancer chemoprevention. Cancer Prev Res (Phila) 2013;6:401-9
40. Yang CS, Li G, Yang Z, et al. Cancer prevention by tocopherols and tea polyphenols. Cancer Lett 2013; Epub ahead of print
41. Yang CS, Wang X, Lu G, et al. Cancer prevention by tea: Animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009;9:429-39
42. Suzuki K, Yahara S, Hashimoto F, et al. Inhibitory activities of (-)-epigallocatechin-3-o-gallate against topoisomerases i and ii. Biol Pharm Bull 2001;24:1088-90
43. Thakur VS, Gupta K, Gupta S. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class i histone deacetylases. Carcinogenesis 2012;33:377-84
44. Kurahashi N, Sasazuki S, Iwasaki M, et al. Green tea consumption and prostate cancer risk in Japanese men: A prospective study. Am J Epidemiol 2008;167:71-7
45. Bettuzzi S, Brausi M, Rizzi F, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66:1234-40
46. Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: Two years later. A follow-up update. Eur Urol 2008;54:472-3
47. Jian L, Xie LP, Lee AH, et al. Protective effect of green tea against prostate cancer: A case-control study in southeast china. Int J Cancer 2004;108:130-5
48. Nguyen MM, Ahmann FR, Nagle RB, et al. Randomized, double-blind, placebo-controlled trial of polyphenon e in prostate cancer patients before prostatectomy: Evaluation of potential chemopreventive activities. Cancer Prev Res (Phila) 2012;5:290-8
49. Wang P, Aronson WJ, Huang M, et al. Green tea polyphenols and metabolites in prostatectomy tissue: Implications for cancer prevention. Cancer Prev Res (Phila) 2010;3:985-93
50. Jatoi A, Ellison N, Burch PA, et al. A phase ii trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003;97:1442-6
51. Choan E, Segal R, Jonker D, et al. A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary/alternative therapy approach. Urol Oncol 2005;23:108-13
52. Clinical trials: US NIH, ClinicalTrials. gov.. A registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. With most updated information on chemoprevention clinical trials.
53. Strick R, Strissel PL, Borgers S, et al. Dietary bioflavonoids induce cleavage in the mll gene and may contribute to infant leukemia. Proc Natl Acad Sci USA 2000;97:4790-5
54. Plichart M, Menegaux F, Lacour B, et al. Parental smoking, maternal alcohol, coffee and tea consumption during pregnancy and childhood malignant central nervous system tumours: The escale study (sfce). Eur J Cancer Prev 2008;17:376-83
55. Laviano A, Rianda S, Molfino A, et al. Omega-3 fatty acids in cancer. Curr Opin Clin Nutr Metab Care 2013;16:156-61
56. Chua ME, Sio MC, Sorongon MC, et al. Relationship of dietary intake of omega-3 and omega-6 fatty acids with risk of prostate cancer development: A meta-analysis of prospective studies and review of literature. Prostate Cancer 2012;2012:826254
57. Berquin IM, Min Y, Wu R, et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 2007;117:1866-75
58. Kobayashi N, Barnard RJ, Henning SM, et al. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin e2. Clin Cancer Res 2006;12:4662-70
59. Aronson WJ, Kobayashi N, Barnard RJ, et al. Phase ii prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res (Phila) 2011;4:2062-71
60. Berquin IM, Edwards IJ, Chen YQ. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 2008;269:363-77
61. Szymanski KM, Wheeler DC, Mucci LA. Fish consumption and prostate cancer risk: A review and meta-analysis. Am J Clin Nutr 2010;92:1223-33
62. Gerber M. Omega-3 fatty acids and cancers: A systematic update review of epidemiological studies. Br J Nutr 2012;107(Suppl 2):S228-39
63. Terry P, Lichtenstein P, Feychting M, et al. Fatty fish consumption and risk of prostate cancer. Lancet 2001;357:1764-6
64. Aronson WJ, Glaspy JA, Reddy ST, et al. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology 2001;58:283-8
65. Demark-Wahnefried W, Robertson CN, Walther PJ, et al. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology 2004;63:900-4
66. Brasky TM, Darke AK, Song X, et al. Plasma phospholipid fatty acids and prostate cancer risk in the select trial. J Natl Cancer Inst 2013;105(15):1132-41
67. Clarke JD, Dashwood RH, Ho E. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 2008;269:291-304
68. Juge N, Mithen RF, Traka M. Molecular basis for chemoprevention by sulforaphane: A comprehensive review. Cell Mol Life Sci 2007;64:1105-27
69. Kolonel LN, Hankin JH, Whittemore AS, et al. Vegetables, fruits, legumes and prostate cancer: A multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000;9:795-804
70. Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000;92:61-8
71. Shapiro TA, Fahey JW, Dinkova-Kostova AT, et al. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: A clinical phase i study. Nutr Cancer 2006;55:53-62
72. Kensler TW, Chen JG, Egner PA, et al. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, Peoples Republic of China. Cancer Epidemiol Biomarkers Prev 2005;14:2605-13
73. Myzak MC, Tong P, Dashwood WM, et al. Sulforaphane retards the growth of human pc-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) 2007;232:227-34
74. Traka M, Gasper AV, Melchini A, et al. Broccoli consumption interacts with gstm1 to perturb oncogenic signalling pathways in the prostate. PLoS One 2008;3:e2568
75. Favus MJ, Langman CB. Evidence for calcium-dependent control of 1,25-dihydroxyvitamin d3 production by rat kidney proximal tubules. J Biol Chem 1986;261:11224-9
76. DeLuca HF. Overview of general physiologic features and functions of vitamin d. Am J Clin Nutr 2004;80:1689S-96S
77. Berger U, Wilson P, McClelland RA, et al. Immunocytochemical detection of 1,25-dihydroxyvitamin d receptors in normal human tissues. J Clin Endocrinol Metab 1988;67:607-13
78. Wang Y, Zhu J, DeLuca HF. Where is the vitamin d receptor Arch Biochem Biophys 2012;523:123-33
79. Wang X, Studzinski GP. Activation of extracellular signal-regulated kinases (erks) defines the first phase of 1,25-dihydroxyvitamin d3-induced differentiation of hl60 cells. J Cell Biochem 2001;80:471-82
80. Shabahang M, Buras RR, Davoodi F, et al. 1,25-dihydroxyvitamin d3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 1993;53:3712-18
81. Simboli-Campbell M, Narvaez CJ, Tenniswood M, et al. 1,25- Dihydroxyvitamin d3 induces morphological and biochemical markers of apoptosis in mcf-7 breast cancer cells. J Steroid Biochem Mol Biol 1996;58:367-76
82. Ylikomi T, Laaksi I, Lou YR, et al. Antiproliferative action of vitamin d. Vitam Horm 2002;64:357-406
83. Welsh J. Cellular and molecular effects of vitamin d on carcinogenesis. Arch Biochem Biophys 2012;523:107-14
84. Swami S, Krishnan AV, Feldman D. Vitamin d metabolism and action in the prostate: Implications for health and disease. Mol Cell Endocrinol 2011;347:61-9
85. Banach-Petrosky W, Ouyang X, Gao H, et al. Vitamin d inhibits the formation of prostatic intraepithelial neoplasia in nkx3.1;pten mutant mice. Clin Cancer Res 2006;12:5895-901
86. Ahonen MH, Tenkanen L, Teppo L, et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin d levels (Finland). Cancer Causes Control 2000;11:847-52
87. Osborn JL, Schwartz GG, Smith DC, et al. Phase ii trial of oral 1,25-dihydroxyvitamin d (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1995;1:195-8
88. Muindi JR, Peng Y, Potter DM, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 2002;72:648-59
89. Marshall DT, Savage SJ, Garrett-Mayer E, et al. Vitamin d3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab 2012;97:2315-24
90. Liu MM, Huang Y, Wang J. Developing phytoestrogens for breast cancer prevention. Anticancer Agents Med Chem 2012;12:1306-13
91. Nur € Ozten-KandaşMCB. Chemoprevention of prostate cancer: natural compounds, antiandrogens, and antioxidants-in vivo evidence. J Carcinogenisis 2011;10:27
92. Hamilton-Reeves JM, Rebello SA, Thomas W, et al. Effects of soy protein isolate consumption on prostate cancer biomarkers in men with hgpin, asap, and low-grade prostate cancer. Nutr Cancer 2008;60:7-13
93. Konijeti R, Henning S, Moro A, et al. Chemoprevention of prostate cancer with lycopene in the tramp model. Prostate 2010;70:1547-54
94. de Souza PL, Russell PJ, Kearsley JH, et al. Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. Nutr Rev 2010;68:542-55
95. Society AC. Cancer facts and figures 2013. American Cancer Society; Atlanta, Ga: 2013
96. Cazzaniga M, Bonanni B. Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol 2012;2012:985620
97. Palozza P, Colangelo M, Simone R, et al. Lycopene induces cell growth inhibition by altering mevalonate pathway and ras signaling in cancer cell lines. Carcinogenesis 2010;31:1813-21
98. Teodoro AJ, Oliveira FL, Martins NB, et al. Effect of lycopene on cell viability and cell cycle progression in human cancer cell lines. Cancer Cell Int 2012;12:36
99. Qiu X, Yuan Y, Vaishnav A, et al. Effects of lycopene on protein expression in human primary prostatic epithelial cells. Cancer Prev Res (Phila) 2013;6(5):419-27
100. Shen J, Barrios RJ, Jaiswal AK. Inactivation of the quinone oxidoreductases nqo1 and nqo2 strongly elevates the incidence and multiplicity of chemically induced skin tumors. Cancer Res 2010;70:1006-14
101. Henderson CJ, Wolf CR. Disruption of the glutathione transferase pi class genes. Methods Enzymol 2005;401:116-35
102. Sporn MB, Liby KT. Is lycopene an effective agent for preventing prostate cancer Cancer Prev Res (Phila) 2013;6:384-6
103. Ilic D, Misso M. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: A systematic review. Maturitas 2012;72:269-76
104. Huang J, Plass C, Gerhauser C. Cancer chemoprevention by targeting the epigenome. Curr Drug Targets 2011;12:1925-56
105. Khan N, Adhami VM, Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer 2010;17:R39-52
106. Subramanian L, Youssef S, Bhattacharya S, et al. Resveratrol: Challenges in translation to the clinic-a critical discussion. Clin Cancer Res 2010;16:5942-8. Nice review of challenges to develop resveratrol as anticancer and chemopreventive agents.
107. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res 2004;24:2783-840
108. Scott E, Steward WP, Gescher AJ, et al. Resveratrol in human cancer chemoprevention-choosing the right dose. Mol Nutr Food Res 2012;56:7-13
109. Yuan H, Young CY, Tian Y, et al. Suppression of the androgen receptor function by quercetin through protein-protein interactions of sp1, c-jun, and the androgen receptor in human prostate cancer cells. Mol Cell Biochem 2010;339:253-62
110. Nemeth K, Plumb GW, Berrin JG, et al. Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur J Nutr 2003;42:29-42
111. McCann SE, Ambrosone CB, Moysich KB, et al. Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in western New York. Nutr Cancer 2005;53:33-41
112. Zhang DD. The nrf2-keap1-are signaling pathway: The regulation and dual function of nrf2 in cancer. Antioxid Redox Signal 2010;13:1623-6
113. Kelloff GJ, Higley HR, Brawer MK, et al. Chemoprevention strategies in the prostate: An overview. Rev Urol 2002;4:69-77
114. Shukla S, Gupta S. Dietary agents in the chemoprevention of prostate cancer. Nutr Cancer 2005;53:18-32